Tag: MASLD


  • Fatty Liver Cure: Could Pemafibrate and Telmisartan Reversethe Disease?

    Fatty Liver Cure: Could Pemafibrate and Telmisartan Reversethe Disease?

    New Study Suggests a Surprising Duo for Fatty Liver Cure Fatty liver disease, or MASLD/NAFLD as it’s increasingly called, has earned its reputation as a global silent killer. The condition unfolds quietly as excess fat accumulates in liver cells, potentially progressing to inflammation, fibrosis, and even cirrhosis or liver cancer. While lifestyle changes remain the…

  • Fatty Liver Cure: Pemafibrate and Telmisartan Combo May Reverse MASLD

    Fatty Liver Cure: Pemafibrate and Telmisartan Combo May Reverse MASLD

    New hope in fatty liver disease: a drug combination that could reverse MASLD Fatty liver disease, now increasingly called MASLD (Metabolic Associated Steatosis with Liver Disease), affects millions worldwide and is rising in prevalence alongside obesity and sedentary lifestyles. While lifestyle changes remain essential, researchers have long searched for therapies that can halt or reverse…

  • Fatty Liver Cure: How Two Common Cardiovascular Drugs Could Reverses Fatty Liver Disease

    Fatty Liver Cure: How Two Common Cardiovascular Drugs Could Reverses Fatty Liver Disease

    The Breakthrough: A New Hope for Fatty Liver Disease Fatty liver disease, or MASLD (formerly NAFLD), affects millions worldwide and has long lacked a proven medical cure. A recent study from researchers at the University of Barcelona suggests a provocative approach: combining two widely used cardiovascular drugs—pemafibrate and telmisartan—to actively reduce liver fat and improve…

  • Repurposed antihypertensive and lipid-lowering drugs show promise against MASLD

    Repurposed antihypertensive and lipid-lowering drugs show promise against MASLD

    New hope for MASLD through drug repurposing Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the world’s most common liver disorder, affecting roughly one in three adults. It involves fat buildup in liver cells and is linked to serious liver outcomes and a heightened risk of cardiovascular mortality. A recent study from the University of…

  • Repurposed Antihypertensive and Lipid-Lowering Drugs Show Promise Against MASLD

    Repurposed Antihypertensive and Lipid-Lowering Drugs Show Promise Against MASLD

    MASLD: A Global Liver Disease in Need of Safe, Effective Treatments Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as the world’s most common liver disorder, affecting roughly one in three adults. The disease is characterized by fat buildup in liver cells, which can progress to liver dysfunction and is closely linked to higher…

  • Rising MASLD Cases: Exams, AI Roles, and Prevention in Fatty Liver

    Rising MASLD Cases: Exams, AI Roles, and Prevention in Fatty Liver

    Understanding the Surge in MASLD Fatty liver disease is increasingly common worldwide, with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) emerging as the predominant form. Global estimates place the prevalence around 38% among adults, with a notable 15% increase over the last two decades. MASLD often coexists with metabolic disorders such as obesity, type 2 diabetes,…

  • Rising Fatty Liver Cases (+15%): Tests, AI Tools, and MasLD Insights

    Rising Fatty Liver Cases (+15%): Tests, AI Tools, and MasLD Insights

    Rising fatty liver cases: what MasLD means for health Recent expert discussions highlight a worrying rise in fatty liver disease. Known as Metabolic dysfunction-associated steatotic liver disease (MasLD), this condition now affects a large share of adults worldwide and is increasingly recognized as a major public health challenge. MasLD describes the abnormal buildup of fat…

  • Fatty Liver Surge (+15%): Tests, Monitoring, and the Role of AI

    Fatty Liver Surge (+15%): Tests, Monitoring, and the Role of AI

    What is MASLD and why are cases rising? Global health experts are sounding the alarm over a sharp rise in fatty liver disease, now often referred to as MASLD (Metabolic dysfunction-associated steatotic liver disease). Recent estimates place the condition in roughly 38% of the adult population worldwide, representing a 15% increase compared with two decades…

  • Identifying Risk Factors for Fatal Liver Disease

    Identifying Risk Factors for Fatal Liver Disease

    Understanding the Growing Threat of MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become a pressing health concern globally. With rates on the rise, it’s crucial to identify the underlying risk factors that contribute to this debilitating condition. Recent research highlights three main cardiometabolic risk factors: high blood pressure, type 2 diabetes, and low levels…

  • Three Major Risk Factors for Deadly Liver Disease Identified

    Three Major Risk Factors for Deadly Liver Disease Identified

    Understanding Metabolic-Associated Steatotic Liver Disease (MASLD) Metabolic-Associated Steatotic Liver Disease (MASLD) is a serious condition marked by excessive fat accumulation in the liver. This ailment is increasingly prevalent worldwide, largely attributed to rising obesity rates, sedentary lifestyles, and poor nutrition. Recent research has shed light on three primary cardiometabolic risk factors that heighten the risk…